The action of atogepant involves blocking the activity of CGRP, a neuropeptide that plays a significant role in the development of migraines. CGRP is released during a migraine attack and is involved in transmitting and modulating pain signals. By inhibiting the CGRP receptor, atogepant prevents the binding of CGRP to its receptors, thus reducing the activity of CGRP and its effects.
The spectrum of atogepant explicitly targets migraines and is not indicated for treating other conditions. It is intended for use in adults who experience migraines, and its effectiveness in other types of headaches or pain disorders has not been established.